INTRODUCTION
Aortic stenosis (AS) is the most common acquired valvular heart disease, occurring in about 5% of patients above 65 years of age [1] . AS is a chronic disease, with the mean survival estimated at two to five years depending on the severity of symptoms [2] . Medical treatment and balloon valvuloplasty do not prolong life in patients with symptomatic AS. In patients with severe AS, the treatment of choice is surgical aortic valve replacement (SAVR) with implantation of a mechanical or biological valve prosthesis.
Longterm outcomes of SAVR are good but depend on the presence of concomitant conditions and patient's age [3] , which may increase the surgical risk. Due to perioperative mortality concerns in older patients with multiple comorbidi ties, often after previous cardiac surgery, and with unfavour able anatomy, about 33% of patients with severe AS are not candidates for surgical treatment [4] .
With the novel therapeutic approach of transcatheter aortic valve implantation (TAVI) introduced by a French cardiologist Alain Cribier in 2002, therapeutic options in
TAVI OUTCOMES IN RELATION
TO SURGICAL RISK The effectiveness and safety of TAVI procedures in comparison to SAVR were evaluated since the very introduction of tran scatheter procedures into the clinical practice. Obviously, first experiences and comparisons were in patients at the highest, prohibitive surgical risk. In subsequent years, with technologi cal advances in the valve prostheses themselves, valve stents, and delivery systems, the spectrum of candidates for TAVI has expanded, in clinical trials as well as in common prac tice. Recently, research projects have been undertaken that include not only intermediate and highrisk patients but also lowrisk patients (PARTNER 3 Trial -The Safety and Effective ness of the SAPIEN 3 Transcatheter Heart Valve in LowRisk Patients With Aortic Stenosis (P3), NCT02675114; Medtronic Transcatheter Aortic Valve Replacement in LowRisk Patients, NCT02701283).
Below, we briefly review the most important clinical stud ies on the effectiveness and safety of TAVI, starting with the most recent reports on lowsurgicalrisk patients.
Low-risk patients
In the randomised NOTION study, the efficacy and safety of SAVR and TAVI was compared in unselected patients (allcomers) at the mean age of 79.1 years. In the study group, 81.8% of patients were low risk (Society of Thoracic Surgeons [STS] score < 4%). Twoyear mortality and stroke incidence were similar in both groups (9.8% vs. 8.0%, p = 0.54; and 5.4% vs. 3.6%, p = 0.46, respectively) [13, 14] .
The prospective German GARY registry showed compa rable mortality with SAVR and TAVI in higherrisk groups but lower mortality with SAVR in lowrisk groups [15] .
In 2016, three large randomised clinical trials were initi ated that compare the efficacy of SAVR and TAVI in low-risk patients, including the PARTNER 3 study with the Edwards Sapien 3 bioprosthesis (STS score < 4%, age ≥ 65 years, NCT02675114), the Medtronic Transcatheter Aortic Valve Replacement in LowRisk Patients study with the Medtronic Evolute R bioprosthesis (STS score < 3%, no age restric tions, NCT02701283), and the NOTION2 study using Symetis, Lotus, and Portico bioprostheses (allcomer study, NCT02825134).
Intermediate-risk patients
The randomised PARTNER 2 study compared SAVR and TAVI (using the balloonexpandable Sapien 3 bioprosthesis) in a group of patients with severe AS at intermediate surgical risk (STS score 4-8%). The mean patient age in the TAVI group was 81.5 years, and the STS score was 5.8% in each group. This study showed no differences in the rate of a combined endpoint that included allcause mortality and stroke [15] . In patients treated using the femoral approach, a statistically significant lower rate of the combined endpoint was shown compared to surgical treatment (HR = 0.79, p = 0.05, intentiontotreat) [7] .
In the randomised SURTAVI study using selfexpandable bioprostheses (CoreValve Evolute R), SAVR was compared with TAVI in a moderatesurgicalrisk group. The mean pa tient age was 79 years, and the STS score was 4.5%. At two years of followup, the combined endpoint rate (allcause mortality and stroke) was 14.0% in the SAVR group and 12.6% in the TAVI group. The rates of periprocedural renal failure, atrial fibrillation, and the need for blood transfu sions were higher in the SAVR group, while a residual perivalvular leak and the need for pacemaker implantation were more common in the TAVI group [13] . It should be noted that only 16% of the TAVI patients were treated with secondgeneration valve (Evolute R), while 84% were treated with the first-generation CoreValve, and that the vast majority of operators who participated in the SURTAVI trial had very limited experience in performing TAVI procedures prior to the study (the prerequisite for participation was experience of more than 40 cases).
After these studies were reported in 2016, Sapien 3 and CoreValve Evolute R bioprostheses received Conformité Européenne (CE) and Food and Drug Administration (FDA) certificates for transcatheter treatment of severe AS in mod eratesurgicalrisk patients.
High-risk and prohibitive-risk patients
In an arm of the PARTNER 1 study (cohort A), the efficacy and safety of SAVR and TAVI via the femoral and transapical approach (using the balloonexpandable Edwards Sapien bioprosthesis) was compared in patients with severe AS at a high surgical risk (STS score ≥ 10%). The mean patient age was 84 years, the mean STS score was 11.7 ± 3.5% in the SAVR group vs. 11.8 ± 3.3% in the TAVI group, and the mean logistic EuroSCORE was 29.2 ± 15.6% vs. 29.3 ± 16.5%, respectively. At one year and five years, mortality was comparable in the SAVR and TAVI groups (26.8% vs. 24.2% and 62.4% vs. 67.8%, p < 0.76, respectively). The stroke rate at five years was also similar (11.3% vs. 10.4%, p = 0.61) [8, 16] .
A comparison of SAVR and TAVI using selfexpandable CoreValve prostheses in patients with severe AS at high surgical risk (30day mortality risk ≥ 15%) was performed in the CoreValve US Pivotal HighRisk Trial. The mean patient age was 83 years, and the STS score was 7.4%. Oneyear mortality in the SAVR group was significantly higher compared to the TAVI group (19.1% vs. 14.2%, p < 0.04). At one year, a non-significant trend for a higher stroke rate was noted in the SAVR group (12.6% vs. 8.8%, p = 0.1) [4] . Survival at three years was similar in both groups (39.1% vs. 32.9%, p = 0.07) while the stroke rate was significantly higher in the SAVR group (19.0% vs. 12.6%, p = 0.03) [17] .
In cohort B of the PARTNER 1 study, which included patients who were not deemed candidates for SAVR due to extremely (prohibitive) high surgical risk, medical treatment was compared to TAVI using a balloonexpandable Edwards Sapien bioprosthesis implanted by the femoral approach. The mean patient age in the PARTNER 1 study was 83 years, the mean STS score was 12.1 ± 6.1% in the medical treatment group vs. 11.2 ± 5.8% in the TAVI group, and the mean logistic EuroSCORE was 30.4 ± 19.1% vs. 26.4 ± 17.2%, respectively. Surgery was contraindicated if the expected 30day risk of death and major irreversible surgical complications was above 50%. Oneyear mortality was 50.7% in the medical treatment group compared to 30.7% in the TAVI group (p < 0.001) [6] , and five-year mortality was 93.6% vs. 71.8%, respectively (p < 0.001). The stroke rate at five years was 18.2% vs. 16.0%, respectively (p = 0.56) [18] . The authors concluded that TAVI prolonged life in inoperable patients who were previously only treated medically.
The effectiveness of TAVI in veryhighrisk patients was also confirmed using self-expandable bioprostheses in the nonrandomised CoreValve US Pivotal Trial ExtremeRisk Iliofemoral Study. The mean patient age was 83.2 years, and the mean STS score was 10.3%. At one year, the combined endpoint rate (allcause mortality and stroke) was 26%, the mortality rate was 24.3%, and stroke rate was 4.3% [19] .
PATIENT SELECTION CRITERIA
FOR TAVI PROCEDURES Treatment decisions in patients with AS require determination of the risk of SAVR and consideration of the clinical status of the patient. According to the European Society of Cardiology (ESC) guidelines, the recommended risk scores in patients with valvular heart disease are the STS score and the EuroSCORE II. Based on the proposed SAVR risk calculators, patients may be divided into four risk groups. Low risk is defined as STS score < 4% and EuroSCORE II < 4%, moderate risk as STS score 4-8% and EuroSCORE II 4-8%, high risk as STS score ≥ 8% and EuroSCORE II ≥ 8% (or log EuroSCORE ≥ 20%), and very high (prohibitive) risk is defined as the expected 30day risk of death and major irreversible surgical complica tions above 50% [9, 20, 21] .
The proposed risk calculators do not include all factors that are associated with increased surgical risk [22] . When selecting patients for SAVR or TAVI, additional factors that have not been included in the STS score and EuroSCORE II should be taken into account, including severe calcification of the ascending aorta (porcelain aorta), previous chest radiotherapy, chest deformations, osteoporosis, active malignancy, and oth ers. In all cases, the decision regarding the optimal treatment approach in a patient with severe symptomatic AS should be made by a multidisciplinary Heart Team that includes an invasive cardiologist, cardiac surgeon, cardiovascular imag ing specialist, and anaesthesiologist experienced in patient selection for, and performance of, TAVI procedures [9, 23] . In some cases, a gerontologist should be part of the Heart Team, in order to evaluate the expected benefit in quality of life in a specific patient.
The recently issued focusupdated AHA/ACC guidelines recommend the following patient selection criteria for TAVI ( Fig. 1 ) [24] : -For patients in whom TAVI or highrisk SAVR is being considered, a heart valve team consisting of an integrated, multidisciplinary group of healthcare professionals with ex pertise in valvular heart disease, cardiac imaging, interven tional cardiology, cardiac anaesthesia, and cardiac surgery should collaborate to provide optimal patient care (IC); -SAVR or TAVI is recommended for symptomatic pa tients with severe AS and high risk for SAVR, depending on patient-specific procedural risks, values, and preferences (IA); -TAVI is recommended for symptomatic patients with severe AS and a prohibitive risk for SAVR, who have a pre dicted postTAVI survival greater than 12 months (IA); -TAVI is a reasonable alternative to SAVR for symptomatic patients with severe AS and intermediate surgical risk, depending on patient-specific procedural risks, values, and preferences (IIaB);
-Percutaneous aortic balloon dilation may be considered as a bridge to SAVR or TAVI for symptomatic patients with severe AS (IIbC); -TAVI is not recommended in patients in whom existing comorbidities would preclude the expected benefit from correction of AS (IIIB).
CONTRAINDICATIONS TO TAVI According to the 2012 ESC guidelines, absolute contraindi cations to TAVI procedures include no cardiac surgical unit available in the TAVI centre, life expectancy less than one year, too small (< 18 mm) or too large (> 30 mm) aortic annulus, left ventricular (LV) thrombus, endocarditis, and high risk of coronary artery ostium occlusion.
Relative contraindications include LV ejection fraction (LVEF) below 20%, and haemodynamic instability.
Regardless of these ESC guidelines, the abovementioned PARTNER studies and FRANCE 2 and TARIS registries identi fied factors that may adversely affect treatment outcomes in patients selected for TAVI [25, 26] . These include: -LVEF < 30%, pulmonary hypertension (mean pulmonary artery pressure > 25 mm Hg), lowgradient AS, low stroke volume index (< 35 mL/m 2 ), and significant organic mitral regurgitation in patients with cardiovascular disease; -oxygen therapy in patients with chronic lung disease; -atrial fibrillation and dialysis therapy in patients with advanced renal failure. Currently available aortic valve bioprosthesis deploy ment systems allow valve implantation using a transvascular approach through a femoral artery (used in 80-90% of TAVI procedures), subclavian artery (usually left), right internal carotid, as well as transcaval approach. If no vascular ap proach is possible, e.g. due to extensive atherosclerotic le sions, some bioprostheses (e.g. Sapien, Symetis, JenaValve) may be implanted using the apical approach. In some cases, vascular access may also be obtained by direct puncture of the ascending aorta following anterior ministernotomy or lateral minithoracotomy.
CHOICE OF VALVE PROSTHESIS
Currently available prostheses may be implanted in pa tients with the native aortic annulus size of 18 mm to 30 mm, or perimeter of the aortic annulus in the range 56-94 mm, or area of the aortic annulus between 338 mm 2 and 683 mm 2 , depending on the manufacturer's specification.
According to some authors, transoesophageal echo cardiography is the standard imaging method to measure the aortic annulus diameter, although in clinical practice, measurements of aortic annulus circumference (perimeter) or area by multislice computed tomography (MSCT) are more important for planning TAVI procedures. MSCT also allows precise evaluation of other key anatomic parameters for selecting an appropriate bioprosthesis type, including the width and height of coronary sinuses, the distance between coronary ostia and the level of aortic annulus or aortic cusp attachments, the angle of aortic entry to the left ventricle, the width of the LV outflow tract, presence of ascending aortic calcifications, and others.
AngioMSCT is also an excellent method to evaluate the course and the diameter of femoral and iliac arteries. These measurements are necessary for the choice of the optimal vascular access site for introduction and passage of the valve deployment system. Vascular sheaths used to introduce the valve deployment system are sized 14-20 F. The minimum femoral and iliac artery lumen diameter for safe passage of the valve deployment system is 5-6 mm.
PERFORMANCE OF TAVI PROCEDURES
-VASCULAR ACCESS Detailed evaluation and choice of the vascular access site is one of the initial important steps when selecting patients for TAVI. MSCT is the reference imaging method to evaluate femoral, iliac, subclavian, and in some patients also carotid arteries. The extent of imaging should include the whole vascular segment from the vascular access site to the native aortic valve annulus. MSCT al lows evaluation of the arterial lumen diameter and course, along with the presence of possible stenoses or calcifications.
Currently, the following access sites are used for TAVI pro cedures: 1. Transvascular, via:
-femoral artery; -subclavian artery; -axillary artery; -carotid artery; -vena cava inferior and abdominal aorta (transcaval ap proach).
Transthoracic, via:
-lateral minithoracotomy -transapical approach; -ministernotomy or rightsided minithoracotomydirect aortic approach. The most commonly used approach for TAVI procedures is via the right or left common femoral artery. The last step of TAVI procedure is to obtain haemostasis at the vascular access site. If the vessel used was not exposed surgically, the femoral artery access site may be closed by percutaneous preclosing suture technique using the Prostar or Proglide (Abbott) clo sure devices. Small femoral or iliac artery wall ruptures with extravasation seen on angiography are usually be treated with prolonged balloon inflation or stentgraft implantation.
If the femoral access was obtained by surgical vessel exposure, the femoral artery access site is closed surgically.
Subclavian/axillary artery approach requires cooperation with a vascular surgeon. The left subclavian artery is usu ally used, allowing favourable, more axial alignment of the inserted valve prosthesis in relation to the native aortic valve annulus. Following subclavian artery puncture and insertion of an appropriate vascular sheath, the next steps are similar to those with the femoral artery approach.
The transapical approach is usually used when no access via the femoral or subclavian/axillary artery is possible. The procedure is performed through the fifth or sixth left intercostal space laterally to the sternum, following precise localisation of the LV apex by palpation and echocardiography.
The transapical and direct aortic approaches are cardiac surgical procedures. TAVI procedures, particularly when us ing surgical access, should be performed in hybrid operation rooms, combining surgical theatre and cardiac catheterisation laboratory capabilities.
Following TAVI procedure, an immediate drop in aortic valve pressure gradient is observed, usually to several mm Hg. If a more than mild perivalvular regurgitant leak is identi fied by echocardiography immediately after the procedure, specific measures should be taken in order to minimise the perivalvular leak: if the mechanism is insufficient expansion, a post balloon inflation should be deployed, if the reason is too high or too low implantation, a second valve should be implanted, etc.). This is particularly important as moderate or large perivalvular leaks may be associated with increased longterm mortality. The regurgitant leak does not usually in crease by serial echocardiographic evaluation during one year of followup. Improvement of LV systolic function, reduction of functional mitral regurgitation, and significant improvement of exercise tolerance as measured by the New York Heart Association class have also been reported.
Transcatheter aortic valve implantation procedures via the femoral artery approach are increasingly commonly performed under conscious sedation with local anaesthesia only, without the use of general anaesthesia, and in some centres, even without the presence of an anaesthesiologist in the room [27] . When combined with percutaneous femoral artery closure, this allows early patient mobilisation (even as early as the next day) and rehabilitation followed by rapid hospital discharge.
PERIPROCEDURAL DRUG THERAPY
The strategy of periprocedural drug therapy remains to be debated. Most authors agree that patients should receive a loading acetylsalicylic acid (ASA) dose (300 mg), and in most cases also a loading clopidogrel dose (300 mg) before the TAVI procedure. However, this is not a routine approach, particularly in patients with increased bleeding risk (by the HASBLED score) or when a surgical (transapical or direct aortic) approach is planned.
Immediately before the procedure, patients receive a sin gle antibiotic dose and unfractionated heparin to increase the activated clotting time above 250 s.
In patients with atrial fibrillation and other indications for oral anticoagulant therapy, the drug should be withdrawn 2-3 days before the procedure and replaced with lowmo lecularweight heparin given subcutaneously. Following TAVI, these patients are usually treated with an oral anticoagulant (acenocoumarol or warfarin) combined with a single an tiplatelet agent (ASA or clopidogrel) for 1-3 months. Oral anticoagulant monotherapy may also be considered.
No systematic data are available regarding use of novel oral anticoagulants (NOAC) in patients after TAVI. Randomised studies, such as GALILEO, are underway.
In patients without indications for chronic anticoagula tion, dual antiplatelet therapy is used to prevent thrombosis of the aortic valve prosthesis for 1-6 months after TAVI, using daily maintenance doses of 75-100 mg of ASA (continued indefinitely) and 75 mg of clopidogrel (for up to six months) [28] [29] [30] [31] [32] [33] [34] [35] .
Patients with renal failure require particular attention. Contrastinduced nephropathy should be prevented, primar ily by appropriate periprocedural hydration and possibly by administering large Nacetylcysteine doses. Attention should be paid to the amount of contrast agent administered during the procedure -this is usually limited to 60-100 mL.
POST-PROCEDURAL MANAGEMENT
The primary aims of postprocedural management include monitoring and treatment of postprocedural complications, and early patient mobilisation and rehabilitation.
Following the procedure, the patient is usually monitored in an intensive cardiac care unit for 1-2 days or, in the case of transapical or direct aortic approach that required thora cotomy, in a postoperative care unit.
The most common complications during this period include bleeding at the vascular access site, other vascular complications, cardiac arrhythmias, stroke, acute heart failure, or respiratory failure [29] .
Regardless of the approach used, a temporary pacing lead is left in the right ventricle for 48 h in all patients without an implanted pacemaker, due to the risk of new heart block.
The need for permanent pacemaker implantation due to a new cardiac conduction block following implantation of an aortic valve prosthesis ranges from a few per cent of patients treated with balloonexpanded Edwards Sapien XT/Sapien 3 prostheses to 30% of patients treated with selfexpandable CoreValve Evolute R prostheses [36, 37] .
In experienced TAVI centres, the mean duration of hos pital stay following TAVI procedures is up to five days for the femoral approach and up to seven days for other approaches [29] . Based on the POLTAVI registry data, the mean duration of hospital stay following TAVI procedures in Polish centres is seven days.
COMPLICATIONS OF TAVI PROCEDURES
In the published registries and observational studies, 30day mortality following TAVI by a transfemoral/transsubclavian approach ranges from 0% to 25% [38] [39] [40] [41] . In the randomised multicentre PARTNER study that compared outcomes of TAVI using the Edwards Sapien prosthesis and medical treatment in inoperable AS patients (cohort B), oneyear mortality was reduced by 20% [6] .
Vascular access site complications have been reported in the literature on TAVI. In patients treated with transvascular (transfemoral/transsubclavian) approach, these included peripheral vessel rupture, acute arterial occlusion or stenosis, and major bleeding requiring surgical intervention. These complications were reported in 9-20% of patients [38] [39] [40] [41] .
Patients undergoing TAVI by a transapical approach are primarily at risk of chest wall bleeding and, rarely, bleeding at the LV apex puncture site. The reported rate of surgical interventions due to bleeding following TAVI by a transapical approach is 8-14% [42] [43] [44] . Development of LV pseudoaneu rysm is another very rare but severe complication in patients treated using a transapical approach [45] .
Implantation of a permanent cardiac pacemaker was required within 30 days of TAVI in 3.4% of patients treated with an EdwardsSapien valve in the PARTNER study and in 33.3% of patients in the British CoreValve registry [37] . In the latter, independent predictors of permanent cardiac pacemaker implantation included occurrence of a new atrio ventricular conduction block during TAVI, balloon angioplasty immediately before valve implantation, use of a larger valve prosthesis, interventricular septal thickness, and increased preprocedural QRS width. In the Dutch registry, preproc edural QRS width and interventricular septal thickness were identified as independent predictors of permanent cardiac pacemaker implantation [36] . A larger rate of pacemaker implantation following treatment with selfexpandable valve prostheses has been attributed to compression of the basal segment of the interventricular septum by the distal segment of a metal stent. The underlying conduction disturbance is usually left bundle branch block (LBBB) that develops in the setting of a pre-existing first-degree atrioventricular block. The rate of permanent cardiac pacemaker implantation has been reduced with advances in procedural technique, and a relation between occurrence of a new LBBB and the depth of valve prosthesis implantation and valve stent penetration into the LV outflow tract has been shown for self-expandable valve prostheses [37] .
In more recent multicentre registries, a stroke rate of 2-4% at one year after TAVI has been reported. Introduction of dedicated neuroprotection systems offers some hope for a further reduction of periprocedural stroke rate, but the cur rently available evidence is equivocal.
The learning curve has a major effect on TAVI out comes. The Vancouver group reported a trend (p = 0.09) for lower survival among the first 25 patients who underwent a TAVI procedure compared to the next 25 patients [40] . The experience with the first 30 patients who underwent TAVI at the Institute of Cardiology in Warsaw shows that inhospital mortality was 6.6% vs. 0%, and 90day survival was 80% vs. 93%, respectively, when the first 15 patients were com pared with the subsequent 15 patients [46] .
TAVI IN PERSPECTIVE
Transcatheter aortic valve implantation procedures are cur rently the only alternative treatment approach in inoperable or surgical highrisk patients with severe, symptomatic AS. All randomised clinical trials showed that in terms of safety, TAVI outcomes were at least comparable to SAVR in patients at high or moderate surgical risk, while the effectiveness of TAVI was also comparable or even better. Also, TAVI outcomes in lowsurgicalrisk patients were comparable to the surgical treatment group. Further studies in this patient group are underway. The major problems associated with TAVI include the learning curve, vascular complications, bleeding, strokes, and cardiac conduction blocks requiring implantation of a permanent cardiac pacemaker. With further advances in valve prosthesis design, miniaturisation of deployment sys tems, introduction of neuroprotection devices, and advances in TAVI procedural technique, the complication rate is likely to decrease. In addition, new types of valve prostheses, cur rently evaluated in animal and clinical studies, will allow better adjustment of the valve prosthesis and deployment system to the anatomical and clinical characteristics of the patient (tailored therapy), which should result in even better safety and effectiveness of TAVI procedures. This is a main condition to broaden in future transcatheter treatment of AS into the younger patient's cohort with lowrisk patients.
In the near future, as TAVI will probably be performed in patients with low risk as well, and patient selection for TAVI will be based more on anatomical suitability regardless of surgical risk or the patient's age. Better cardiac imaging will allow a more precise prediction of the procedure as well as better selection of the specific device to be used. Improved devices that will be dedicated for TAVI procedures in a bicus pid aortic valve stenosis will expand the indication for TAVI to this wide part of the population with aortic valve stenosis, who are not optimal candidates for TAVI today, unless they are at high or prohibitive risk for surgery.
The next step in TAVI is just around the corner. On July 14 th , 2017, the first patient was recruited into the EARLY TAVR (Evaluation of Transcatheter Aortic Valve Replacement Compared to SurveilLance for Patients with AsYmptomatic Severe Aortic Stenosis) randomised (vs. standard of care), multicentre trial [47] . This important trial will evaluate whether there is benefit from replacing the aortic valve via a minimally invasive, catheterbased procedure before patients develop symptoms. The goal of early TAVI is to preserve the heart's function, and prevent further heart deterioration and death.
